Deal Watch Asia Focus: Merck Partners With Alibaba For Entry To Digital Health In China

 
• By Ian Haydock, Anju Ghangurde, Jung Won Shin, and Joseph Haas

China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.

DealWatch_1200x675

More from Deals

More from Business